Several distributor agreements in Europe for smart needle company Injeq
Free for publication 17.2.2022 at 13:00 EET
The Finnish medical technology company Injeq Oy has entered into distribution agreements in Italy, Austria, France and Slovenia.
In addition to the agreements now announced, Injeq has distributor agreements in Germany and the Nordic countries, including Finland. In total, the markets of nine countries cover about half of the European medical technology market as a whole.
Injeq's distributor strategy is to partner with innovative medium-sized or smaller companies that know their customers personally and are experts in Injeq's product segment. “We have worked purposefully and systematically to build a distributor network. Now the results are starting to show”, says Injeq's Sales Director Seppo Lautamäki.
The aim of the IQ-Tip® smart needle is to improve patient safety in lumbar punctures, where spinal fluid is sampled, or when drugs are administered into the spinal cavity. The smart needle tells you in real time when the tip of the needle reaches the cerebrospinal fluid, increasing the likelihood of a successful puncture.
In December, the IQ-Tip® smart needle received CE certification from the EU's notified body, TÜV SÜD Product Service GmbH. This enables the devices to be sold in EU countries. The global market for special needles is projected to grow from approximately $ 9.5 billion (2020) to $ 16.9 billion by 2027. The estimated annual growth is 8.5 percent.
For further information, please contact:
Injeq Oy
Seppo Lautamäki, VP Sales
Tel. +358 40 5560 166
seppo.lautamaki@injeq.com
Injeq in brief
Injeq Oy is a Finnish growth company in innovative medical technology, whose mission is to produce technically intelligent solutions for medically demanding patient injections. Developed at the request of physicians, the IQ-Tip® smart needle facilitates physicians' work to improve patient safety and treatment effectiveness.
The IQ-Tip® smart needle is a modern way to perform demanding patient injections safely. The first stage is lumbar puncture, a clinical procedure in which the spinal fluid is sampled or a drug is administered into the spinal cavity. The clinical performance and safety of the product at lumbar punctures have been evaluated in three clinical trials in Finnish university hospitals. The smart needle is suitable for lumbar puncture from newborns to the elderly, one of the main uses being for the treatment of leukemia children.
Founded in 2010, Injeq operates in Tampere and currently employs 16 people. Injeq is supported by an experienced team of medical experts and extensive scientific research. IQ-Tip® is a registered trademark of Injeq.
www.injeq.com